Stockscreener 앱 받기
15.88
5.59%
0.84
시간 외 거래:
15.91
0.03
+0.19%
전일 마감가:
$15.04
열려 있는:
$14.78
하루 거래량:
306.67K
Relative Volume:
1.64
시가총액:
$696.35M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+9.59%
1개월 성능:
+9.44%
6개월 성능:
+33.78%
1년 성능:
+0.00%
1일 변동 폭
$14.27
$16.20
1주일 범위
$14.16
$16.40
52주 변동 폭
$6.71
$18.67
Maze Therapeutics Inc Stock (MAZE) Company Profile
명칭
Maze Therapeutics Inc
전화
(650) 850-5070
주소
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
MAZE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
15.88 | 659.52M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-02 | 개시 | BTIG Research | Buy |
| 2025-07-23 | 개시 | H.C. Wainwright | Buy |
| 2025-07-08 | 개시 | Wedbush | Outperform |
Maze Therapeutics Inc 주식(MAZE)의 최신 뉴스
What MACD and RSI say about Maze Therapeutics Inc.2025 Investor Takeaways & Capital Efficiency Focused Strategies - Newser
Visual analytics tools that track Maze Therapeutics Inc. performance2025 Volatility Report & Verified Entry Point Detection - Newser
Is Maze Therapeutics Inc. showing signs of accumulationJuly 2025 Earnings & AI Enhanced Market Trend Forecasts - Newser
Risk vs reward if holding onto Maze Therapeutics Inc.Earnings Overview Summary & AI Powered Market Trend Analysis - Newser
Will Maze Therapeutics Inc. benefit from sector rotationEarnings Trend Report & Real-Time Market Sentiment Reports - خودرو بانک
Risk adjusted return profile for Maze Therapeutics Inc. analyzed2025 Stock Rankings & Community Trade Idea Sharing Platform - Newser
What’s the recovery path for long term holders of Maze Therapeutics Inc.Market Performance Recap & Weekly Return Optimization Alerts - Newser
What is Maze Therapeutics Inc.’s book value per share2025 Bull vs Bear & Stepwise Entry and Exit Trade Signals - خودرو بانک
Can Maze Therapeutics Inc. disrupt its industryIPO Watch & Daily Profit Maximizing Trade Tips - خودرو بانک
Is Maze Therapeutics Inc. a cyclical or defensive stock2025 Geopolitical Influence & Verified Swing Trading Watchlists - خودرو بانک
Should you wait for a breakout in Maze Therapeutics Inc.July 2025 Analyst Calls & Advanced Technical Analysis Signals - Newser
Maze Therapeutics Inc. stock chart pattern explainedPortfolio Profit Report & Daily Chart Pattern Signal Reports - Newser
Custom strategy builders for tracking Maze Therapeutics Inc.M&A Rumor & Consistent Growth Stock Picks - Newser
Sentiment analysis tools applied to Maze Therapeutics Inc.Portfolio Value Report & Intraday High Probability Setup Alerts - Newser
Using data models to predict Maze Therapeutics Inc. stock movementStop Loss & Precise Swing Trade Alerts - Newser
Understanding Maze Therapeutics Inc.’s price movementOptions Play & Daily Profit Focused Stock Screening - Newser
What indicators show strength in Maze Therapeutics Inc.July 2025 Setups & AI Enhanced Trading Signals - Newser
Statistical indicators supporting Maze Therapeutics Inc.’s strengthBreakout Watch & Weekly High Return Stock Forecasts - Newser
Maze Therapeutics Inc. stock volume spike explained2025 EndofYear Setup & Free Fast Gain Swing Trade Alerts - Newser
Can Maze Therapeutics Inc. grow without dilutionDividend Hike & Verified Technical Signals - خودرو بانک
Multi asset correlation models including Maze Therapeutics Inc.Risk Management & Weekly Chart Analysis and Guides - Newser
Maze Therapeutics’ Claims For Unapproved Kidney Disease Drug Face Regulatory Scrutiny - insights.citeline.com
Should value investors consider Maze Therapeutics Inc.July 2025 Levels & Growth Focused Stock Reports - khodrobank.com
Is it too late to sell Maze Therapeutics Inc.Market Growth Report & Breakout Confirmation Trade Signals - Newser
Maze Therapeutics appoints Misbah Tahir as chief financial officer - Investing.com India
Maze Therapeutics initiated with a Buy at BTIG - TipRanks
BTIG initiates coverage on Maze Therapeutics with a Buy rating and PT of $30. - AInvest
Maze Therapeutics appoints Tahir as Chief Financial Officer - TipRanks
Maze Therapeutics Names Misbah Tahir as Chief Financial Officer - MarketScreener
Maze Therapeutics Appoints Misbah Tahir as CFO - TipRanks
Maze Therapeutics appoints Misbah Tahir as chief financial officer By Investing.com - Investing.com UK
Maze Therapeutics Names Misbah Tahir as New CFO. - AInvest
Maze Therapeutics Appoints Misbah Tahir as New CFO - AInvest
Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer - GlobeNewswire
Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer - GlobeNewswire Inc.
BTIG Initiates Maze Therapeutics at Buy With $30 Price Target - MarketScreener
Is Maze Therapeutics Inc. stock showing strong momentum2025 Institutional Moves & Technical Pattern Recognition Alerts - خودرو بانک
How to monitor Maze Therapeutics Inc. with trend dashboardsWeekly Trend Recap & Real-Time Buy Signal Alerts - Newser
Can Maze Therapeutics Inc. outperform in the next rallyLayoff News & Community Verified Trade Signals - خودرو بانک
Will Maze Therapeutics Inc. stock recover after earningsWeekly Investment Recap & AI Driven Stock Movement Reports - خودرو بانک
Maze Therapeutics Inc. Breakout Confirmed by Volume Metrics getLinesFromResByArray error: size == 0 - 강소기업뉴스
Institutional scanner results for Maze Therapeutics Inc.2025 Top Gainers & Technical Confirmation Trade Alerts - Newser
Historical volatility pattern of Maze Therapeutics Inc. visualizedTrade Signal Summary & Real-Time Volume Triggers - Newser
Can trapped investors hope for a rebound in Maze Therapeutics Inc.2025 Earnings Impact & Daily Volume Surge Trade Alerts - Newser
Maze Therapeutics Inc (MAZE) 재무 분석
Maze Therapeutics Inc (MAZE)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.40%
자본화:
|
볼륨(24시간):